Skip to main content
SpringerLink
Log in

Association of digoxin therapy with case fatality rate in acute pulmonary embolism

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Objective

Despite wide usage of digoxin for various diseases in cardiology practice, its benefit is controversial and moreover it had been associated with unfavorable outcomes in some previous studies. The aim of this present study was to demonstrate whether digoxin usage was related with worse outcomes or not in patients with acute pulmonary embolisms.

Methods

A total number of 1215 patients retrospectively enrolled for the study. Basic demographic features, pulmonary embolism severity index (PESI) scores, laboratory parameters and medications of patients who had been diagnosed with acute pulmonary embolism were recorded. Short (30 days) and long-term mortality were reported as the clinical outcomes.

Results

Total mortality was 15.4% in the study population and 78 of these subjects died within the first 30 days. The frequency of digoxin treatment was 8% and most of these patients were prior users. According to the binary logistic regression analyses the PESI score, right ventricle (RV) diastolic diameter, systolic pulmonary arterial pressure (sPAP), brain natriuretic peptide (BNP), troponin and digoxin therapy (odds ratio, OR: 2.82 95% confidence interval, CI: 1.39–8.31, P = 0.03) were found as independent predictors of short-term mortality. Beside these findings; sPAP, PESI score, RV diastolic diameter and digoxin therapy (hazard ratio, HR: 2.11 95%CI: 1.22–7.31, P = 0.03) were determined as independent predictors of long-term mortality in Cox regression analyses. In subgroup analysis, we determined significantly greater increase in short-term mortality with use of digoxin among patients who had chronic renal disease, among patients under thrombolytic therapy and under high dosage of digoxin therapy and among female patients.

Conclusion

Digoxin has been used extensively for decades in the treatment of heart failure and arrhythmias despite some controversies over its benefit. For the first time in the literature, we have demonstrated independent association of digoxin therapy with short-term and long-term mortality in patients with acute pulmonary embolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.

    Article  Google Scholar 

  2. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831–8.

    Article  CAS  Google Scholar 

  3. Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063–74.

    Article  CAS  Google Scholar 

  4. Metawee M, Charnigo R, Morales G, et al. Digoxin and short term mortality after acute STEMI: results from the MAGIC trial. Int J Cardiol. 2016;218:176–80.

    Article  Google Scholar 

  5. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–9.

    Article  CAS  Google Scholar 

  6. Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65(25):2691–8.

    Article  CAS  Google Scholar 

  7. Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.

    Article  CAS  Google Scholar 

  8. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.

    Article  CAS  Google Scholar 

  9. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.

    Article  CAS  Google Scholar 

  10. Eisen A, Ruff CT, Braunwald E, et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2017;6(7):e6035.

    Article  Google Scholar 

  11. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370–2.

    Article  CAS  Google Scholar 

  12. Oh JK, Seward JB, Tajik AJ. The echo manual. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 401–15.

    Google Scholar 

  13. Konstantinides SV, Torbicki A, Skoro-Sajer N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Russ J Cardiol. 2015; https://doi.org/10.15829/1560-4071-2015-8-67-110.

    Article  Google Scholar 

  14. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.

    Article  Google Scholar 

  15. Gheorghiade M, Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA. 2009;302(19):2146–7.

    Article  Google Scholar 

  16. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403–11.

    Article  CAS  Google Scholar 

  17. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed. J Am Coll Cardiol. 2009;53(15):e1–e90.

    Article  Google Scholar 

  18. Leor J, Goldbourt U, Rabinowitz B, et al. Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. Cardiovasc Drugs Ther. 1995;9(5):723–9.

    Article  CAS  Google Scholar 

  19. Alajaji W, Baydoun A, Al-Kindi SG, et al. Digoxin therapy for cor pulmonale: a systematic review. Int J Cardiol. 2016;223:320–4.

    Article  Google Scholar 

  20. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.

    Article  CAS  Google Scholar 

  21. Mina GS, Acharya M, Shepherd T, et al. Digoxin is associated with increased shock events and electrical storms in patients with implantable cardioverter defibrillators. J Cardiovasc Pharmacol Ther. 2018;23(2):142–8.

    Article  CAS  Google Scholar 

  22. Virgadamo S, Charnigo R, Darrat Y, et al. Digoxin: a systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015;7(11):808.

    Article  Google Scholar 

  23. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the heart and estrogen/progestin replacement study: lessons learned. Circulation. 2002;105(8):917–22.

    Article  Google Scholar 

  24. Aebi S, Schnider TW, Los G, et al. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol. 1999;44(3):259–65.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Siyami Ersek Cardiovascular and Thoracic Surgery Center, Siyami Ersek Hospital, Tıbbıye street, Uskudar, Istanbul, Turkey

    Mehmet Baran Karataş M.D., Nizamettin Selçuk Yelgeç M.D., Yiğit Çanga M.D., Ahmet Zengin M.D. & Ayşe Emre M.D.

Authors
  1. Mehmet Baran Karataş M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nizamettin Selçuk Yelgeç M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiğit Çanga M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmet Zengin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ayşe Emre M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yiğit Çanga M.D..

Ethics declarations

Conflict of interest

M.B. Karataş, N.S. Yelgeç, Y. Çanga, A. Zengin, and A. Emre declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karataş, M.B., Yelgeç, N.S., Çanga, Y. et al. Association of digoxin therapy with case fatality rate in acute pulmonary embolism. Wien Klin Wochenschr 133, 1171–1178 (2021). https://doi.org/10.1007/s00508-020-01773-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-020-01773-z

Keywords

Search

Navigation